Characteristic | Cohort 1Â N (%) | Cohort 2Â N (%) | Cohort 3Â N (%) |
---|---|---|---|
No. of patients, N | 60 | 14 | 9 |
Sex | |||
 Male | 42 (70 %) | 8 (57.1 %) | 6 (66.7 %) |
 Female | 18 (30 %) | 6 (42.9 %) | 3 (33.3 %) |
Age, median years (range) | 54 (27–81) | 59.5(40–76) | 65 (42–82) |
Tumor classification | |||
 Cholangiocarcinoma | 10 (16.7 %) | 0 | 2 (22.2 %) |
 Colon cancer | 7 (11.7 %) | 1 (7.1 %) | 0 |
 Gastric cancer | 7 (11.7 %) | 0 | 0 |
 Lung cancer | 11 (18.3 %) | 4 (28.6 %) | 2 (22.2 %) |
 Primary liver cancer | 25 (41.7 %) | 1 (7.1 %) | 2 (22.2 %) |
 Other | 0 | 8 (57.1 %) | 3 (33.3 %) |
TNM staging | |||
 Stage I | 3 (5 %) | 1 (7.1 %) | 2 (22.2 %) |
 Stage II | 4 (6.7 %) | 0 | 1 (11.1 %) |
 Stage IIIA | 12 (20 %) | 2 (14.3 %) | 1 (11.1 %) |
 Stage IIIB | 2 (3.3 %) | 0 | 0 |
 Stage IIIC | 9 (15 %) | 4 (28.6 %) | 1 (11.1 %) |
 Stage IV | 27 (45 %) | 6 (42.9 %) | 3 (33.3 %) |
 Missing data | 3 (5 %) | 1 (7.1 %) | 1 (11.1 %) |
Adjuvant therapeutic strategies | |||
 Without | 24 (40 %) | 5 (35.7 %) | 7 (77.8 %) |
 With | 36 (60 %) | 9 (64.3 %) | 2 (22.2 %) |
 Chemotherapy | 18 (30 %) | 6 (42.9 %) | 1 (11.1 %) |
 Radiation therapy | 8 (13.3 %) | 1 (7.1 %) | 1 (11.1 %) |
 Physiotherapy | 2 (3.3 %) | 0 | 1 (11.1 %) |
 Interventional treatment | 9 (15 %) | 2 (14.3 %) | 0 |
 Molecular targeted therapy | 2 (3.3 %) | 1 (7.1 %) | 0 |